Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 13/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742795 | 0.91 | CYP19A1 (0.63) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL5503331 | 0.82 | CYP19A1 (0.84) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL15942726 | 0.79 | KCNH2 (0.56) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL22340138 | 0.78 | CYP19A1 (0.76) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL31254014 | 0.78 | CYP19A1 (0.49) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL22340189 | 0.77 | KCNH2 (0.56) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL5854511 | 0.76 | CYP19A1 (0.78) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL19410272 | 0.76 | CYP19A1 (0.62) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL2069507 | 0.75 | ALOX12 (0.74) | KCNH2TRPV1CYP19A1ALOX12ALOX15 | |
| SCHEMBL29559241 | 0.75 | ALOX12 (0.74) | KCNH2TRPV1CYP19A1ALOX12ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103641808-B | The enantioselective hydrogenation method of chromene | GIRINDUS AMERICA INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| CN-103755675-B | The enantioselective hydrogenation method of chromene | GIRINDUS AMERICA INC. (US) | 2015-11-18 | — | — | CN | disclosed |
| EP-1919887-B1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| CN-101535286-B | Process for the enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-05-07 | — | — | CN | disclosed |
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | disclosed |
| CN-103755675-A | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-04-30 | — | — | CN | disclosed |
| CN-103641808-A | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-03-19 | — | — | CN | disclosed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-7528267-B2 | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1919887-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Girindus America, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007016423-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
| EP-0944613-B1 | BENZOPYRAN DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6153768-A | RECEPTOR BLOCKING ANTIESTROGENS HAVING REDUCED SIDE EFFECTS | C & C RESEARCH LABORATORIES (KR) | 2000-11-28 | — | — | US | disclosed |
| EP-0944613-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C Research Laboratories (KR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025916-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | KCNH2 2508/4885TRPV1 3412/4885CYP19A1 194/4885 |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | HRH3, HRH2, CHD8 | KCNH2 2508/4885TRPV1 3412/4885CYP19A1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.